Compare BCPC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCPC | TNGX |
|---|---|---|
| Founded | 1967 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.5B |
| IPO Year | 1995 | 2020 |
| Metric | BCPC | TNGX |
|---|---|---|
| Price | $179.01 | $26.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $176.00 | $21.78 |
| AVG Volume (30 Days) | 176.3K | ★ 2.0M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | 20.87 | ★ 26.89 |
| EPS | ★ 2.63 | N/A |
| Revenue | ★ $799,023,000.00 | $62,384,000.00 |
| Revenue This Year | $8.47 | N/A |
| Revenue Next Year | $4.89 | N/A |
| P/E Ratio | $67.18 | ★ N/A |
| Revenue Growth | 13.56 | ★ 48.29 |
| 52 Week Low | $139.17 | $6.25 |
| 52 Week High | $183.90 | $34.39 |
| Indicator | BCPC | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 67.55 | 47.03 |
| Support Level | $159.54 | $19.74 |
| Resistance Level | $183.45 | $28.41 |
| Average True Range (ATR) | 4.13 | 1.65 |
| MACD | 1.48 | -0.02 |
| Stochastic Oscillator | 86.74 | 39.23 |
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.